Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T07:54:36.951Z Has data issue: false hasContentIssue false
  • English
  • Français

Recent Developments in Health Law: States Lead the Way on Health Insurance Reform

Published online by Cambridge University Press:  01 January 2021

Eric Benson
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
JLME Column
Information
Journal of Law, Medicine & Ethics , Volume 35 , Issue 2 , Summer 2007 , pp. 329 - 339
Copyright
Copyright © American Society of Law, Medicine and Ethics 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

The American Journal of Law & Medicine has been tracking and contributing to the development of health law since its inception at Boston University School of Law in 1975. The Journal publishes articles authored by professors, attorneys, physicians, and other health care professionals on subjects ranging from health law and policy to the legal, ethical, and economic aspects of medical practice, research, and education.

The Harvard Law & Health Care Society is a student-operated health law organization at Harvard University Law School. In addition to contributing to this column, the Harvard Law & Health Care Society also hosts speakers from private practice and academia, presents career panels, and promotes interdisciplinary dialogue with other Harvard University graduate schools.

References

References

Bush, G. W., “The State of the Union,” January 23, 2007, available at <http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=2007_record&docid=cr23ja07–120> (last visited March 20, 2007).+(last+visited+March+20,+2007).>Google Scholar
See e.g., Edwards, J., “Universal Health Care through Shared Responsibility,” February 5, 2007, available at <http://johnedwards.com/about/issues/healthcare-overview.pdf> (last visited February 13, 2007). Edwards's “shared responsibility” proposal relies on an individual mandate, government subsidies, employer assessments, and purchasing pools, all of which are central elements of both the Massachusetts and California plans. See also Broder, D., “Health Coverage's Momentum,” Washington Post, February 4, 2007, at B07, available at <http://www.washingtonpost.com/wp-dyn/content/article/2007/02/02/AR2007020201547.html> (last visited March 20, 2007). (last visited March 20, 2007).' href=https://scholar.google.com/scholar?q=See+e.g.,+Edwards,+J.,+“Universal+Health+Care+through+Shared+Responsibility,”+February+5,+2007,+available+at++(last+visited+February+13,+2007).+Edwards's+“shared+responsibility”+proposal+relies+on+an+individual+mandate,+government+subsidies,+employer+assessments,+and+purchasing+pools,+all+of+which+are+central+elements+of+both+the+Massachusetts+and+California+plans.+See+also+Broder,+D.,+“Health+Coverage's+Momentum,”+Washington+Post,+February+4,+2007,+at+B07,+available+at++(last+visited+March+20,+2007).>Google Scholar
Schwarzenegger consulted experts on the Massachusetts reforms to guide development of his proposal. Krasner, J., “California's Health Care Plan Looks Familiar,” Boston Globe, January 11, 2007, at D1, available at <http://www.boston.com/business/healthcare/articles/2007/01/11/califs_healthcare_plan_looks_familiar/> (last visited March 20, 2007). (last visited March 20, 2007).' href=https://scholar.google.com/scholar?q=Schwarzenegger+consulted+experts+on+the+Massachusetts+reforms+to+guide+development+of+his+proposal.+Krasner,+J.,+“California's+Health+Care+Plan+Looks+Familiar,”+Boston+Globe,+January+11,+2007,+at+D1,+available+at++(last+visited+March+20,+2007).>Google Scholar
Belluck, P., “Massachusetts Could Serve as a Guide in California's Health Insurance Bid,” New York Times, January 10, 2006, available at <http://www.nytimes.com/2007/01/10/us/10mass.html?ex=1170910800&en=c567226b2ee52b40&ei=5070> (last visited March 20, 2007; article is password protected) . (last visited March 20, 2007; article is password protected) .' href=https://scholar.google.com/scholar?q=Belluck,+P.,+“Massachusetts+Could+Serve+as+a+Guide+in+California's+Health+Insurance+Bid,”+New+York+Times,+January+10,+2006,+available+at++(last+visited+March+20,+2007;+article+is+password+protected)+.>Google Scholar
Members include the state secretary of Administration and Finance, the executive director of the state Group Insurance Commission, the state director of Medicaid, the commissioner of the state Division of Insurance, a health economist, an actuary, a representative of small business, a representative of a health consumer organization, an employee health benefit specialist, and a representative of organized labor. Mass. Gen. Laws ch. 176Q, § 2(b) (2006).Google Scholar
Mass. Gen. Laws ch. 111M, § 2(b) (2006).Google Scholar
Id.Google Scholar
The Connector will set affordability standards later this spring. Commonwealth Health Insurance Connector Authority, “Timetable: Process for Developing Regulations,” January 11, 2007, available at <http://www.mass.gov/Qhic/docs/Timetable%20-%20Process%20for%20Developing%20Regs.xls> (last visited March 20, 2007) .+(last+visited+March+20,+2007)+.>Google Scholar
Mass. Gen. Laws ch. 176Q, §3(a)(5) (2006).Google Scholar
Mass. Gen. Laws ch. 111M, § 2(a) (2006).Google Scholar
Commonwealth Health Insurance Connector Authority, “3rd Tier Product Specifications,” February 6, 2007, available at <http://www.mass.gov/Qhic/docs/3rd-Tier%20Specifications.doc> (last visited March 20, 2007).+(last+visited+March+20,+2007).>Google Scholar
Commonwealth Health Insurance Connector Authority, “Policy Committee Data: MCC Overview,” January 19, 2007, available at <http://www.mass.gov/Qhic/docs/Policy%20Committee%20Data%20(01-19-06).xls> (last visited March 20, 2007).+(last+visited+March+20,+2007).>Google Scholar
Mass. Gen. Laws ch. 175, § 108(2)(a)(3) (2006); Mass. Gen. Laws ch. 176A, § 8Z (2006); Mass. Gen. Laws ch. 176B, § 4Z (2006); Mass. Gen. Laws ch. 176G, § 4R (2006).Google Scholar
Mass. Gen. Laws ch. 176J, § 10 (2006).Google Scholar
Mass. Gen. Laws ch. 176Q, § 4 (2006).Google Scholar
Massachusetts Division of Insurance and Market Merger Special Commission, “Impact of Merging the Massachusetts Non-Group and Small Group Health Insurance Markets,” December 26, 2006, at 10, available at <http://www.mass.gov/Eoca/docs/doi/Legal_Hearings/Non-Grp_SmallGrp/FinalReport_12_26.pdf> (last visited March 20, 2007 .+(last+visited+March+20,+2007+.>Google Scholar
Mass. Gen. Laws ch. 118H (2006). FPL is currently $9,800 for an individual. See 71 Federal Register 3848–3849.Google Scholar
Mass. Gen. Laws ch. 118H, § 6 (2006).Google Scholar
Mass. Regs. Code tit. 956, § 3.11 (H)(2) (2006).Google Scholar
Commonwealth Health Insurance Connector Authority, Press Release, Connector Authority Expands Access to Health Coverage, January 23, 2007, at 1, available at <http://www.mass.gov/Qhic/docs/worcester_pr_1.23.doc> (last visited March 20, 2007) (hereinafter cited as Commonwealth).+(last+visited+March+20,+2007)+(hereinafter+cited+as+Commonwealth).>Google Scholar
Day, R., Operations Report by Deputy Director Rosemarie Day, paper presented at the Massachusetts Connector Board meeting, Boston, MA, February 8, 2007.Google Scholar
Massachusetts Executive Office of Health and Human Services, Press Release, Survey Reveals 88,000 Reduction Among State's Uninsured, August 28, 2006, at 1, available at <http://www.mass.gov?pageID=pressreleases&agId=Eeohhs2&prModName=eohhspressrelease&prFile=pr_060828_uninsured_numbers_reduced.xml> (last visited March 20, 2007) (hereinafter cited as Massachusetts). (last visited March 20, 2007) (hereinafter cited as Massachusetts).' href=https://scholar.google.com/scholar?q=Massachusetts+Executive+Office+of+Health+and+Human+Services,+Press+Release,+Survey+Reveals+88,000+Reduction+Among+State's+Uninsured,+August+28,+2006,+at+1,+available+at++(last+visited+March+20,+2007)+(hereinafter+cited+as+Massachusetts).>Google Scholar
Mass. Gen. Laws ch. 149, § 188 (2006); Mass. Gen. Laws ch. 151F, § 2 (2006).Google Scholar
Mass. Regs. Code tit. 114.5, § 16 (2006).CrossRefGoogle Scholar
Mass. Gen. Laws ch. 149, § 188(c)(10) (2006).Google Scholar
Mass. Gen. Laws ch. 151F, § 2 (2006).Google Scholar
Mass. Gen. Laws ch. 118G, §§ 1, 18B(b) (2006).Google Scholar
Mass. Gen. Laws ch. 175, § 110 (2006); Mass. Gen. Laws ch. 176A, § 8 1/2 (2006); Mass. Gen. Laws ch. 176B, § 3B (2006); Mass. Gen. Laws ch. 176G, § 6A (2006).Google Scholar
Health Access, “Preliminary Analysis: Governor Schwarzenegger's Health Care Proposal,” January 17, 2007, at 1, available at <http://www.health-access.org/advocating/docs/Preliminary%20Analysis%20of%20Gov's%20Health%20Care%20Proposal.pdf> (last visited March 20, 2007). (last visited March 20, 2007).' href=https://scholar.google.com/scholar?q=Health+Access,+“Preliminary+Analysis:+Governor+Schwarzenegger's+Health+Care+Proposal,”+January+17,+2007,+at+1,+available+at++(last+visited+March+20,+2007).>Google Scholar
California Office of the Governor, “Governor's Health Care Proposal,” January 8, 2007, at 6, available at <http://www.health-access.org/advocating/docs/Governor's%20HC%20Proposal.pdf> (last visited March 20, 2007) (hereinafter cited as California). (last visited March 20, 2007) (hereinafter cited as California).' href=https://scholar.google.com/scholar?q=California+Office+of+the+Governor,+“Governor's+Health+Care+Proposal,”+January+8,+2007,+at+6,+available+at++(last+visited+March+20,+2007)+(hereinafter+cited+as+California).>Google Scholar
Id., at 5.Google Scholar
Id., at 4, 5.Google Scholar
Id., at 4.Google Scholar
Id., at 7.Google Scholar
Id., at 8.Google Scholar
Id.Google Scholar
Id., at 4; see Health Access, supra note 29, at 3.Google Scholar
“Healthy Actions” programs will provide rewards such as premium reductions or gym memberships to people who participate in “evidence-based practices and behaviors that have been shown to both reduce the burden of disease and are cost effective.” See California Office of the Governor, supra note 30, at 1, 8.Google Scholar
Id., at 7.Google Scholar
Id., at 4.Google Scholar
Id., at 8, 9.Google Scholar
Health Access, “Massachusetts' Health Care Law: Model, Mirage, or Momentum?” June, 2006, at 12, available at <http://www.health-access.org/expanding/docs/MassCalHAFReportFinal.pdf> (last visited March 20, 2007). (“The scope of the problem is almost twice as great in California, where nearly 1 in 5 residents are uninsured, as opposed to in Massachusetts, which is closer to 1 in 10.”) (last visited March 20, 2007). (“The scope of the problem is almost twice as great in California, where nearly 1 in 5 residents are uninsured, as opposed to in Massachusetts, which is closer to 1 in 10.”)' href=https://scholar.google.com/scholar?q=Health+Access,+“Massachusetts'+Health+Care+Law:+Model,+Mirage,+or+Momentum?”+June,+2006,+at+12,+available+at++(last+visited+March+20,+2007).+(“The+scope+of+the+problem+is+almost+twice+as+great+in+California,+where+nearly+1+in+5+residents+are+uninsured,+as+opposed+to+in+Massachusetts,+which+is+closer+to+1+in+10.”)>Google Scholar
Id., at 3. (A more expansive proposal “was pending in a ballot measure for which signatures were already collected by a large coalition of health care and consumer advocates.”)Google Scholar
See Broder, supra note 2. (“As he seeks the GOP nomination, Romney is touting his plan for universal coverage.”)Google Scholar
Massachusetts Executive Office of Health and Human Services, “MassHealth Section 1115 Waiver Amendment,” May 1, 2006, at 3, available at <http://www.mass.gov/Eeohhs2/docs/eohhs/cms_waiver_2006/amendment.pdf> (last visited March 21, 2007). California's waiver is good until 2010. Centers for Medicare and Medicaid Services, “Details for California Medi-Cal Hospital Uninsured Care 1115 Waiver,” November 8, 2005, available at <http://www.cms.hhs.gov/MedicaidStWaivProgDemoPGI/MWDL/itemdetail.asp?filterType=none&filterByDID=0&sortByDID=3&sort0rder=ascending&itemID=CMS042428> (last visited March 20, 2007). (last visited March 20, 2007).' href=https://scholar.google.com/scholar?q=Massachusetts+Executive+Office+of+Health+and+Human+Services,+“MassHealth+Section+1115+Waiver+Amendment,”+May+1,+2006,+at+3,+available+at++(last+visited+March+21,+2007).+California's+waiver+is+good+until+2010.+Centers+for+Medicare+and+Medicaid+Services,+“Details+for+California+Medi-Cal+Hospital+Uninsured+Care+1115+Waiver,”+November+8,+2005,+available+at++(last+visited+March+20,+2007).>Google Scholar
A Healthy Blog, “California Dreamin' II,” Health Care for All Web site, January 10, 2007, available at <http://blog.hcfama.org/?p=758?> (last visited February 13, 2007). (last visited February 13, 2007).' href=https://scholar.google.com/scholar?q=A+Healthy+Blog,+“California+Dreamin'+II,”+Health+Care+for+All+Web+site,+January+10,+2007,+available+at++(last+visited+February+13,+2007).>Google Scholar
See Health Access, supra note 42, at 8.Google Scholar
Id., at 11.Google Scholar
Dembner, A., “200,000 May Need to Get More Insurance,” Boston Globe, January 30, 2007, available at <http://www.boston.com/news/local/articles/2007/01/30/200000_may_need_to_get_more_insurance/> (last visited March 21, 2007). (The consumer advocacy group Health Care for All called for more benefits while the Massachusetts Association of Health Plans, an industry group, called for fewer restrictions).+(last+visited+March+21,+2007).+(The+consumer+advocacy+group+Health+Care+for+All+called+for+more+benefits+while+the+Massachusetts+Association+of+Health+Plans,+an+industry+group,+called+for+fewer+restrictions).>Google Scholar
Mass. Gen. Laws ch. 175, § 110 (2006); Mass. Gen. Laws ch. 176A, § 8 1/2 (2006); Mass. Gen. Laws ch. 176B, § 3B (2006); Mass. Gen. Laws ch. 176G, § 6A (2006).Google Scholar
Wallack, T. and Hollmer, M., “Light Fines May Hamper New Health Law,” Boston Business Journal, November 10, 2007, available at <http://boston.bizjournals.com/boston/stories/2006/11/13/story4.html> (last visited March 21, 2007).+(last+visited+March+21,+2007).>Google Scholar
The Employee Retirement Income Security Act (ERISA) is a federal statute which preempts state laws that require employers to offer specified levels of employee benefits. California's penalty is very similar to a Maryland penalty recently found to be preempted by ERISA. See Retail Industry Leaders Association v. James D. Fielder, 4th Cir. 2007), No. 06–1840, No. 06–1901, 2007 U.S. App. LEXIS 920, available at <http://pacer.ca4.uscourts.gov/opinion.pdf/061840.P.pdf> (last visited March 21, 2007). Because Massachusetts' employer assessment is so small, it is less likely to be preempted by ERISA. (last visited March 21, 2007). Because Massachusetts' employer assessment is so small, it is less likely to be preempted by ERISA.' href=https://scholar.google.com/scholar?q=The+Employee+Retirement+Income+Security+Act+(ERISA)+is+a+federal+statute+which+preempts+state+laws+that+require+employers+to+offer+specified+levels+of+employee+benefits.+California's+penalty+is+very+similar+to+a+Maryland+penalty+recently+found+to+be+preempted+by+ERISA.+See+Retail+Industry+Leaders+Association+v.+James+D.+Fielder,+4th+Cir.+2007),+No.+06–1840,+No.+06–1901,+2007+U.S.+App.+LEXIS+920,+available+at++(last+visited+March+21,+2007).+Because+Massachusetts'+employer+assessment+is+so+small,+it+is+less+likely+to+be+preempted+by+ERISA.>Google Scholar
Mass. Gen. Laws ch. 176M, §§ 3, 4, 5 (2006)Google Scholar
See Health Access, supra note 42, at 4.Google Scholar
California Medical Association, “History of Health Coverage in California,” January 2007, available at <http://www.cma-net.org/upload/health_coverage_history.pdf> (last visited February 13, 2007); see Health Access, supra note 42, at 4 (in California, for-profit insurers “dominate the market”).+(last+visited+February+13,+2007);+see+Health+Access,+supra+note+42,+at+4+(in+California,+for-profit+insurers+“dominate+the+market”).>Google Scholar
Massachusetts House of Representatives, “Register of Seasonably Filed Petitions,” January 2007, at 21, 88, 120, and 143, available at <http://www.mass.gov/legis/07dockets.pdf> (last visited March 21, 2007).+(last+visited+March+21,+2007).>Google Scholar
See e.g., McNamara, E. “Insurance Law Far from Cure,” Boston Globe, January 31, 2007, available at <http://www.boston.com/news/local/articles/2007/01/31/insurance_law_far_from_cure/> (last visited March 21, 2007); see also Dembner, supra note 49.+(last+visited+March+21,+2007);+see+also+Dembner,+supra+note+49.>Google Scholar
See Commonwealth, supra note 20, at 1; Day supra note 21.Google Scholar
See Massachusetts, supra note 22, at 1.Google Scholar
See California, supra note 30, at 2.Google Scholar
Drum, K., “Universal Healthcare in California,” Washington Monthly, January 9, 2007, available at <http://www.washingtonmonthly.com/archives/individual/2007_01/010528.php> (last visited March 21, 2007). (“Tax and budget issues require a two-thirds majority to pass.”)+(last+visited+March+21,+2007).+(“Tax+and+budget+issues+require+a+two-thirds+majority+to+pass.”)>Google Scholar

References

1. University and Small Business Patent Procedures Act, 5 U.S.C. §§ 200-212, 1980.Google Scholar
2. Editorial “Innovation’s Golden Goose,” The Economist, U.S. Ed., December 14, 2002.Google Scholar
3. Fraser, J. and Stevens, A. J., “Understanding the Importance of Bayh Dole,” Euromoney Institutional Investor, December 1, 2005.Google Scholar
4. In 1979, only five percent of the government’s 28,000 patents were licensed to industry, but since 1991, universities have executed 43,862 licenses. Moreover, the number of licenses per year has steadily risen during that time from 1,229 in 1991 to 4,783 in 2004. Association of University Technology Managers, “AUTM Licensing Survey, FY 2004: A Survey Summary of Technology Licensing (and Related) Performance for U.S. Academic and Nonprofit Institutions, and Technology Investment Firms,” 2005, at 24, available at <http://www.autm.net/events/File/04AUTMSurveySum-USpublic.pdf= (last visited March 19, 2007).Google Scholar
5. Leaf, C. and Burke, D., “The Law of Unintended Consequences,” Fortune, September 19, 2005.Google Scholar
6. The incomes from these licenses have also increased rapidly from $218 million in 1991 to $1,385 million in 2004: marking the fifth consecutive year of over $1 billion in licensing revenues. Eighty percent of this revenue comes from running royalties from product sales. See AUTM, supra note 4, at 24.Google Scholar
7. See AUTM, supra note 4, at 14.Google Scholar
8. The Bayh-Dole Act requires this money be spent on “research and education,” but this is not defined and therefore covers an extremely broad array of expenditures. See Leaf and Burke, supra note 5.Google Scholar
9. Commission on Intellectual Property Rights, “Integrating Intellectual Property Rights and Development Policy,” 2002, at 38, available at <http://www.iprcommission.org/papers/pdfs/final_report/CIPRfullfinal.pdf> (last visited March 19, 2007).+(last+visited+March+19,+2007).>Google Scholar
10. Médecins Sans Frontiéres, “Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries,” 9th ed., July 2006, at 5, available at <http://www.accessmed-msf.org/documents/untanglingtheweb%209.pdf> (last visited March 19, 2007).+(last+visited+March+19,+2007).>Google Scholar
11. Universities Allied for Essential Medicine, “Philadelphia Consensus Statement on University Policies for Health-Related Innovations,” November 13, 2006, available at <http://consensus.essentialmedicine.org> (last visited March 21, 2007; article is password protected).+(last+visited+March+21,+2007;+article+is+password+protected).>Google Scholar
12. Id.Google Scholar
13. Kapczynski, A., Chaifetz, S., Katz, Z., and Benkler, Y., “Addressing Global Health Inequities: An Open Licensing Approach for University Innovations,” Berkeley Technology Law Journal 20, no. 2 (2005): 1031-1114, at 1036.Google Scholar
14. Id.Google Scholar
15. Kelly, P., “Choosing the Greater Good in Promotion of UW Intellectual Properties,” University Week, (University of Washington, Seattle) January 4, 2007. The resolution recommends that the UW “affirm that its primary goal in technology transfer is to maximize the worldwide use and societal benefit of its research and technology.”Google Scholar
16. Chokshi, D. A., “Improving Access to Medicines in Poor Countries: The Role of Universities,” PLoS Med 3, no. 6 (2006): e136, 2006, available at <http://medicine.plosjournals.org/perlserv/?request=getdocument&doi=10.1371/journal.pmed.0030136> (last visited March 19, 2007).CrossRefGoogle ScholarPubMed
17. “The leaders of universities have not yet been able to come together around a different approach,” says Leahy. “Regardless of how it is achieved, I believe that increasing the availability of the medical innovations that come from publicly-funded research centers is a sound solution to a pressing global health concern.” Universities Allied for Essential Medicine, Press Release, Senator Leahy Introduces University Licensing Bill, October 6, 2006, available at <http://www.essentialmedicine.org/?p=45> (last visited March 19, 2007).+(last+visited+March+19,+2007).>Google Scholar
18. Public Research in the Public Interest Act of 2006 (senate bill s. 4040), introduced September 29, 2006, available at <http://thomas.loc.gov/cgi-bin/query/z?c109:S.4040:>..>Google Scholar
19. Id., at §3(4). For a list of countries by economic classification, see The World Bank, “Country Classifications, July 1, 2006, available at <http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS0,,contentMDK:20421402~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html> (last visited March 19, 2007).+(last+visited+March+19,+2007).>Google Scholar
20. Id., at §4(a)(2)(B). Neglected diseases are rare diseases for which there is not a sufficient developed-world market that provides a financial incentive to invest in generating a treatment, defined under the act by §526(a)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb(a)(2)). See Public Research in the Public Interest Act, supra note 18, at §3(9).Google Scholar
21. Id., at §3(5)(A-B). In the case where there are multiple patent-holders (e.g., a university and a pharmaceutical company), the parties will be free to contractually stipulate who is to be the recipient of these royalty revenues.Google Scholar
22. Id., at §4(e)(2)Google Scholar
23. A total outlay of $27.7 billion. See AUTM, supra note 4, at 14.Google Scholar
24. Joint Economic Committee, United States Senate, “The Benefits of Medical Research and the Role of the NIH,” 106th Congress 2nd Session: 27, at 4, May 17, 2000, available at <http://hsc.utoledo.edu/research/nih_research_benefits.pdf> (last visited March 20, 2007).+(last+visited+March+20,+2007).>Google Scholar
25. World Health Organization, “Equitable Access to Essential Medicines: A Framework for Collective Action,” 2004, at 1, available at <http://whqlibdoc.who.int/hq/2004/WHO_EDM_2004.4.pdf> (last visited March 20, 2007).+(last+visited+March+20,+2007).>Google Scholar
26. See Kapczynski et al., supra note 13, at 1046.Google Scholar
27. See World Health Organization, supra note 25, at 1.Google Scholar
28. Médecins Sans Frontieres, “Surmounting Challenges: Procurement of Anti-Retroviral Medicines in Low- and Middle-Income Countries,” 2003, at 48, available at <http://www.accessmed-msf.org/documents/procurementreport.pdf> (last visited March 20, 2007).+(last+visited+March+20,+2007).>Google Scholar
29. Over 75 percent of the world’s population live in low- and low-middle income countries. See The World Bank, “World Development Indicators 2006,” April 2006, at 2.1, available at <http://devdata.worldbank.org/wdi2006> (last visited March 19, 2007).+(last+visited+March+19,+2007).>Google Scholar
30. See Médecins Sans Frontiéres, supra note 10, at 5.Google Scholar
31. Central and South America accounted for 2.3 percent of sales, and Central and Eastern Europe 0.9 percent. Sales figures for each of these regions include upper-middle income countries that would not be affected by the legislation (e.g., South Africa, Taiwan, Hong Kong, Korea, Argentina, and the Czech Republic). See Pharmaceutical Research and Manufacturers of America (PhRMA), “Pharmaceutical Industry Profile 2006,” March 2006, at 50, available at <http://www.phrma.org/files/2006%20Industry%20Profile.pdf> (last visited March 19, 2007) (hereinafter cited as PhRMA). See also The World Bank, supra note 19.+(last+visited+March+19,+2007)+(hereinafter+cited+as+PhRMA).+See+also+The+World+Bank,+supra+note+19.>Google Scholar
32. Congress of the United States, Congressional Budget Office, “Research and Development in the Pharmaceutical Industry,” October 2006, at 53, available at <http://www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf> (last visited March 19, 2007) (hereinafter cited as Congress).+(last+visited+March+19,+2007)+(hereinafter+cited+as+Congress).>Google Scholar
33. Id.Google Scholar
34. See PhRMA, supra note 31, at 45Google Scholar
35. See Congress, supra note 32, at 37.Google Scholar
36. Cockburn, I. and Henderson, R., “Publicly Funded Science and the Productivity of the Pharmaceutical Industry,” in Jaffe, A., Lerner, J. and Stern, S., eds., Innovation Policy and the Economy vol. 7 (Cambridge: MIT Press, 2001): at 17.Google Scholar
37. The Human Development Index (HDI) is based on life expectancy, literacy, education, and standard of living. It is used by the United Nations Development Programme in its annual Human Development Report and is available at <http://hdr.undp.org/> (last visited March 19, 2007).+(last+visited+March+19,+2007).>Google Scholar
38. Outterson, K., “Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets,” Yale Journal of Health Policy, Law, and Ethics 5, no. 1 (2004): at 2.Google Scholar
39. See Public Research in the Public Interest Act, supra note 18, at §4(e)(2). See also World Trade Organization General Council, “Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health,” August 30, 2003, at 2(b)(ii), available at <http://www.wto.org/English/tratop_e/trips_e/implem_para6_e.htm> (last visited March 19, 2007).+(last+visited+March+19,+2007).>Google Scholar
40. See Outterson, supra note 38, at 57.Google Scholar
41. See The World Bank, supra note 29, at 4.Google Scholar
42. See Mueller, J. M., “Taking Trips to India – Novartis, Patent Law, and Access to Medicines,” New England Journal of Medicine 356, no. 6 (2007): 541-543. See also “A Novel Prescription,” The Economist, November 9, 2006.CrossRefGoogle ScholarPubMed
43. Bardhan, P., “China, India Superpower? Not so Fast! Despite Impressive Growth, the Rising Asian Giants Have Feet of Clay,” Yale Global, October 25, 2005, available at <http://yaleglobal.yale.edu/display.article?id=6407> (March 19, 2007).+(March+19,+2007).>Google Scholar
44. Most likely, the parties will contractually stipulate that these royalties go to the pharmaceutical company and are counted as sales revenue for the purposes of university royalty payments. This would result in royalty revenues being slightly impacted proportionate to industry sales revenues.Google Scholar
45. Willey, T. F., “Association of University Technology Managers Licensing Survey, FY 1991-FY 1995: Five-Year Survey Summary,” 1996, at 6.Google Scholar

References

1. Freitag, N., “Federal Food and Drug Act Violations,” American Criminal Law Review 41, no. 2 (2004): at 647, 667-669.Google Scholar
2. Dietary Supplement Health and Education Act (DSHEA) of 1994, 42 U.S.C. § 262 (2000). Before enactment of DSHEA, dietary supplements were subject to the same regulatory requirements as other foods. See U.S. FDA, Overview of Dietary Supplements, January 3, 2007, available at <http://vm.cfsan.fda.gov/~dms/ds-oview.html> (last visited January 26, 2007).+(last+visited+January+26,+2007).>Google Scholar
3. Miller, H. and Longtin, D., “Death by Dietary Supplement,” Policy Review, no. 102, August and September 2000, available at <http://hoover.org/publications/policyreview/3486962.html> (last visited February 7, 2007). See also Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999) (holding that the FDA must allow dietary supplement labels to make qualified health claims, which are claims for which there is emerging evidence, albeit evidence not yet sufficient to meet the “significant scientific agreement standard”).Google Scholar
4. 152 Cong. Rec. H9245 (daily ed. December 12, 2006) (statement by Rep. Pallone); Brown, H. A., “Comments: The Need for Regulation Mandating the Labeling of Inactive Ingredients in Pharmaceuticals,” The American University Administrative Law Journal 8 (1994): 303–305; Editorial, “Buyer Beware: Makers of Dietary Supplements Should Have to Prove Safety,” Salt Lake Tribune, August 29, 2006. See also New York State Task Force on Life and the Law, “Dietary Supplements: Balancing Consumer Choice and Safety,” 2005, at 52-68, available at <http://www.health.state.ny.us/regulations/task_force/docs/dietary_supplement_safety.pdf> (last visited February 7, 2007).Google Scholar
5. In 1994, approximately 4,000 dietary supplements were available in the United States. In 2006, an estimated 29,000 dietary supplements, generating over $18 billion in sales, were routinely available at over-the-counter in grocery stories, pharmacies and health food stores. See Lewis, A. S., “Overview of Dietary Supplements,” Gradient Trends, Winter 2006, at 1. The dietary supplement industry’s growth was one of the motivations for Congressional action. 152 Cong. Rec. H9245 (daily ed. Dec. 8, 2006) (statement by Rep. Pallone).Google Scholar
6. NIH, Office of Dietary Supplements, Frequently Asked Questions, available at <http://ods.od.nih.gov/Health_Information/ODS_Frequently_Asked_Questions.aspx#Information> (last visited February 7, 2007); see Miller and Longtin, supra note 3. See also FTC, Bureau of Consumer Protection, Dietary Supplements: An Advertising Guide for Industry, April 2001, at 3,9, available at <http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.pdf> (last visited February 7, 2007).+(last+visited+February+7,+2007);+see+Miller+and+Longtin,+supra+note+3.+See+also+FTC,+Bureau+of+Consumer+Protection,+Dietary+Supplements:+An+Advertising+Guide+for+Industry,+April+2001,+at+3,9,+available+at++(last+visited+February+7,+2007).>Google Scholar
7. DSHEA, 21 U.S.C.A. §§ 321, 342 (2006).CrossRefGoogle Scholar
8. Testimony of Michael F. Mangano, Principal Inspector General for the Department of Health and Human Services, before the Subcommittee on Oversight of Government Management, Restructuring and the District of Columbia, July 31, 2002, at 1.Google Scholar
9. Even the best adverse event reporting systems only detect a small proportion of the events that actually occur. Id., at 3.Google Scholar
10. Consumer medical records, product ingredients and manufacturer identity were all cited as “much needed information” for adequate follow-up, but which the FDA was frequently unable to obtain. Id., at 4-6.Google Scholar
11. The FDA has noted that the dearth of clinical studies and information on consumer use has made it difficult to assess or confirm that a public health problem exists. Id., at 7-9.Google Scholar
12. Senate Report No. 109-324, September 5, 2006, at 4. See also Nixon Peabody L.L.P., “FDA Alert,” January 19, 2007, available at <http://www.nixonpeabody.com/publications_detail3.asp?ID=1669> (last visited January 26, 2007).+(last+visited+January+26,+2007).>Google Scholar
13. U.S. Department of Health and Human Services (DHHS), “Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk,” 21 Code of Federal Regulations Part 119, available at 69 Federal Register 6788-01, 6813.Google Scholar
14. U.S. FDA, “FDA News: Statement from FDA Deputy Commissioner Crawford Regarding Metabolife,” August 15, 2002, available at <http://www.fda.gov/bbs/topics/NEWS/2002/NEW00828.html> (last visited February 7, 2007).+(last+visited+February+7,+2007).>Google Scholar
15. U.S. General Accounting Office (GAO), “Dietary Supplements for Weight Loss: Limited Federal Oversight Has Focused More on Marketing Than on Safety,” GAO-02-985T, July 31, 2002; U.S. GAO, “Dietary Supplements: Review of Health- Related Call Records for Users of Metabolife 356,” GAO-03-494, March 31, 2003). See also CBS News, “Dangerous Enough to Ban?” February 10, 2003, available at <http://www.cbsnews.com/stories/2003/02/10/eveningnews/printable540085.shtml> (last visited February 7, 2007).+(last+visited+February+7,+2007).>Google Scholar
16. Id.Google Scholar
17. See Committee on Health, Education, Labor and Pensions, Senate Report on Dietary Supplement and Nonprescription Drug Consumer Protection Act, No. 109-324, September 5, 2006, at 4.Google Scholar
18. 152 Cong. Rec. S6286 (daily ed. July 21, 2006).Google Scholar
19. Id.Google Scholar
20. Id.Google Scholar
21. DSNDCPA §§ 760(e), 761(e), 21 U.S.C.A. § 371 (2006).Google Scholar
22. See Committee on Health, Education, Labor and Pensions, supra note 17, at 5.Google Scholar
23. Only distributors whose names appear on the label of a dietary supplement or nonprescription drug are subject to this reporting requirement. See DSNDCPA §§ 760(b)(1), 761(b)(1), 21 U.S.C.A. § 371 (2006).Google Scholar
24. Borrowing from the definition used by the FDA’s Safety Information and Adverse Event Reporting Program (“Med- Watch”), a serious adverse event is defined as an adverse event that results in death, a life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect. Id., at § 706(a)(3).Google Scholar
25. Reporting serious adverse events was previously voluntary. Id.Google Scholar
26. DSNDCPA §§ 760, 761, 21 U.S.C.A. § 371 (2006).Google Scholar
27. Id. at §§ 760(e), 761(e) (codified in 21 U.S.C.A. § 371). Authorized employees of the Department of Health and Human Services may access these records. Id.Google Scholar
28. Id. at §§ 760(d), 761(d) (codified in 21 U.S.C.A. § 352) (2006).Google Scholar
29. Id.Google Scholar
30. These releases are subject to the protections of the Privacy Act of 1974 and the Freedom of Information Act. Id. at §§ 760(f ), 761(f ) (codified in 21 U.S.C.A. § 371) (2006).Google Scholar
31. Id., at § 4 (codified in 21 U.S.C.A. § 331) (2006).CrossRefGoogle Scholar
32. Id., at §§ 760(h), 761(h) (codified in 21 U.S.C.A. § 371) (2006).Google Scholar
33. See, e.g., New York State Task Force on Law and the Law, supra note 4, at 19-20.Google Scholar
34. Institute of Medicine, “The Future of Drug Safety: Promoting and Protecting the Health of the Public,” 2006, at 85-90. See also Mangano, supra note 8, at 3; Office of Inspector General (OIG), “U.S. Department of Health and Human Services, Adverse Event Reporting for Dietary Supplements,” OEI-01-00-00180, April 2001, at ii-vi, 5.Google Scholar
35. See OIG, supra note 34, at 10-11.Google Scholar
36. Id.Google Scholar
37. See Mangano, supra note 8, at 4-6.Google Scholar
38. Id.; see OIG, supra note 34, at 20-22.Google Scholar
39. See OIG, supra note 34, at 11-12.Google Scholar
40. Id., at 15-18.Google Scholar
41. See Miller and Longtin, supra note 3.Google Scholar
42. See U.S. FDA, Overview of Dietary Supplements, available at <http://vm.cfsan.fda.gov/~dms/ds-oview.html> (last visited January 26, 2007). Moreover, the lack of standardized testing methods for dietary supplements and nonprescription drugs makes it difficult even for conscientious manufacturers to assure the safety of their product or even to produce reliable ingredient data. A. D. Wait, “Limitations of Test Methods,” Gradient Trends (Winter 2006): at 4.+(last+visited+January+26,+2007).+Moreover,+the+lack+of+standardized+testing+methods+for+dietary+supplements+and+nonprescription+drugs+makes+it+difficult+even+for+conscientious+manufacturers+to+assure+the+safety+of+their+product+or+even+to+produce+reliable+ingredient+data.+A.+D.+Wait,+“Limitations+of+Test+Methods,”+Gradient+Trends+(Winter+2006):+at+4.>Google Scholar
43. The promulgation and subsequent withdrawal of proposed rules for Ephedracontaining supplements highlights the difficulty of regulatory action without sufficient clinical data. See U.S. GAO, “Dietary Supplements: Uncertainties in Analyses Underlying FDA’s Proposed Rule on Ephedrine Alkaloids,” GAO/ HEHS/GGD-99-90, July 1999.Google Scholar
44. See Mangano, supra note 8, at 4-6; see also OIG, supra note 34, at 9.Google Scholar
45. While “responsible parties” may now comply because of the potential penalties, such deception is hardly unprecedented. In 1999, Metabolife told the FDA that it had “never been made aware of any adverse health events by consumers of its products” or “received a notice from a consumer that any serious adverse health event had occurred because of ingestion of Metabolife 356.” Yet a federal investigation revealed that Metabolife was actually holding 16,500 adverse event reports, including at least 2,000 that could be classified as serious. 152 Cong. Rec. S11381, December 6, 2006 (Sen. Durbin).Google Scholar
46. 152 Cong. Rec.S6287, (daily ed. June 21, 2006) (remarks by Sen. Hatch) (discussing attempts to appropriate more funds for the FDA to assist enforcement efforts).Google Scholar
47. See DSHEA § 4, 21 U.S.C. §342(f ) (2000).CrossRefGoogle Scholar
48. Mangano, supra note 8, at 7.Google Scholar
49. See OIG, supra note 34, at 17-18.Google Scholar
50. Id.Google Scholar